###begin article-title 0
Genetic effect of CysLTR2 polymorphisms on its mRNA synthesis and stabilization
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 233 241 233 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CysLTR2 </italic>
We previously demonstrated that single nucleotide polymorphism (SNP) and haplotypes were associated with aspirin hypersensitivity in asthmatics. We investigated the genetic effects of the SNPs and haplotypes on the expression of the CysLTR2 gene.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 105 108 105 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ht1</italic>
###xml 108 112 108 112 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 116 119 116 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ht2</italic>
###xml 119 122 119 122 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
We measured CysLTR2 protein and mRNA expression in EB virus-infected B cell lines from asthmatics having ht1+/+ and ht2+/+. A gel retardation assay was used to identify nuclear protein binding to the c.-819 promoter site. The function of promoter and 3'-UTR were assessed using pGL3 luciferase and pEGFP reporter system, respectively.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 96 99 96 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ht2</italic>
###xml 99 103 99 103 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 124 127 124 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ht1</italic>
###xml 127 130 127 130 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 209 212 209 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ht2</italic>
###xml 212 216 212 216 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 243 246 243 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ht1</italic>
###xml 246 250 246 250 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 363 364 363 364 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 366 376 366 376 <italic xmlns:xlink="http://www.w3.org/1999/xlink">819T than </italic>
###xml 391 392 391 392 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 394 398 394 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink">819G</italic>
###xml 431 432 431 432 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 434 439 434 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink">819T </italic>
###xml 447 455 447 455 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CysLTR2 </italic>
###xml 492 493 492 493 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 495 500 495 500 <italic xmlns:xlink="http://www.w3.org/1999/xlink">819G </italic>
###xml 545 553 545 553 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c.2078T </italic>
###xml 589 597 589 597 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c.2078C </italic>
We found that the expression of CysLTR2 protein was higher in B cell lines of asthmatics having ht2+/+ than in those having ht1+/+. PMA/ionomycin induced higher mRNA expression of CysLTR2 in B cell lines from ht2+/+ asthmatics than those from ht1+/+ asthmatics. A nuclear protein from the B cell lines showed stronger DNA binding affinity with a probe containing c.-819T than one containing c.-819G. The luciferase activity of the c.-819T type of CysLTR2 promoter was higher than that of the c.-819G type. EGFP expression was higher in the EGFP-c.2078T 3'-UTR fusion construct than in the c.2078C construct.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 25 33 25 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CysLTR2 </italic>
The sequence variants of CysLTR2 may affect its transcription and the stability of its mRNA, resulting in altered expression of CysLTR2 protein, which in turn causes some asthmatics to be susceptible to aspirin hypersensitivity.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 242 243 242 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 570 571 570 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 701 702 701 702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 703 704 703 704 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 900 901 900 901 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 1151 1152 1151 1152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 1153 1154 1153 1154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 1169 1170 1169 1170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 1250 1252 1250 1252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 1302 1304 1302 1304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 1305 1307 1305 1307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1323 1325 1323 1325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 1340 1342 1340 1342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 1366 1368 1366 1368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 1369 1371 1369 1371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1829 1831 1829 1831 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 2001 2003 2001 2003 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 2108 2110 2108 2110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 2212 2214 2212 2214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 2342 2344 2342 2344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 2402 2410 2402 2410 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CysLTR2 </italic>
###xml 2437 2438 2437 2438 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 2440 2457 2440 2457 <italic xmlns:xlink="http://www.w3.org/1999/xlink">819G&gt;T, rs7324991</italic>
###xml 2491 2501 2491 2501 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c.2078C&gt;T </italic>
###xml 2505 2534 2505 2534 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c.2534A&gt;G, novel and rs912278</italic>
###xml 2569 2593 2569 2593 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c.2545+297A&gt;G, rs2407249</italic>
###xml 2596 2598 2596 2598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 2658 2659 2658 2659 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 2661 2667 2661 2667 <italic xmlns:xlink="http://www.w3.org/1999/xlink">819G&gt;T</italic>
###xml 2669 2679 2669 2679 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c.2078C&gt;T </italic>
###xml 2682 2692 2682 2692 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c.2534A&gt;G </italic>
###xml 2731 2733 2731 2733 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 2799 2801 2799 2801 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 3058 3061 3058 3061 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ht1</italic>
###xml 3083 3085 3083 3085 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ht</italic>
###xml 3108 3111 3108 3111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ht3</italic>
###xml 3131 3134 3131 3134 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ht4</italic>
###xml 3159 3165 3159 3165 <italic xmlns:xlink="http://www.w3.org/1999/xlink">others</italic>
###xml 3390 3391 3390 3391 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 3391 3393 3391 3393 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 3730 3732 3730 3732 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 3826 3829 3826 3829 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TTG</italic>
###xml 3935 3936 3935 3936 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 3938 3944 3938 3944 <italic xmlns:xlink="http://www.w3.org/1999/xlink">819G&gt;T</italic>
###xml 3949 3957 3949 3957 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CysLTR2 </italic>
###xml 4120 4122 4120 4122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 2173 2181 <span type="species:ncbi:9606">patients</span>
###xml 2281 2286 <span type="species:ncbi:9606">human</span>
Aspirin-intolerant asthma (AIA) refers to the development of bronchoconstriction in asthmatics following the ingestion of aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs). This syndrome is characterized by the 'aspirin triad' [1] syndrome of aspirin hypersensitivity, bronchial asthma, and chronic rhinosinusitis with nasal polyposis. A two-compartment model has been proposed in which both the augmentation of cysteinyl leukotriene (CysLT) production and the overexpression of the CysLT receptor on inflammatory cells occur within the respiratory tract [2]. The overproduction of CysLTs has been demonstrated in the airways and circulation of asthmatics who are intolerant to aspirin [3-5]. CysLTs are important inflammatory mediators in the development of asthma, as they mediate bronchoconstriction while increasing mucus secretion, vascular permeability and cellular infiltration [6]. CysLTs exert their biological actions by binding two types of G-protein-coupled seven-transmembrane receptors: cysteinyl leukotriene receptor 1 (CysLTR1; MIM 300201), which is sensitive to the asthma drugs montelukast, zafirlukast and pranlukast [7,8] and CysLTR2 [9]. CysLTR2 has been documented to be expressed in lung interstitial macrophage [10], pulmonary vascular smooth muscle, endothelium [11-13], eosinophils [14], mast cells [15], B and T lymphocytes [16,17], raising the possibility that CysLTR2 may have an important role in allergic inflammation. Particularly, CysLTR2 may have important role in remodeling and fibrosis pathways in B lymphocytes. Furthermore, CysLTR2 is located on chromosome13q14.2-21.1, near a locus known to be associated with the risk of asthma in various population. CysLTR2 play a disease-regulating role in glands and epithelium of rhinosinusitis, particularly aspirin-sensitive disease [18]. In addition, Cysteinyl-LT signaling may provide a key balance between a release of endothelium-dependent relaxant and constricting factors in endothelium dysfunction [19]. The endothelial CysLTR2 is rapidly down-regulated by pro-inflammatory stimuli in Myocardial Ischemia [20]. A role for CysLTR2 is mediated the coronary constriction in patients with coronary artery disease [21]. CysLTR2 may also contribute to neurological inflammation in the human brain and the adrenal glands of neuroendocrine system [22]. We previously identified four sequence variants of the CysLTR2 gene: one in the promoter (c.-819G>T, rs7324991), two in the 3'-flanking region (c.2078C>T and c.2534A>G, novel and rs912278), and one downstream of the gene (c.2545+297A>G, rs2407249) [20]. We also revealed that asthmatics having rare alleles for c.-819G>T, c.2078C>T or c.2534A>G exhibited a more pronounced drop in FEV1 by aspirin provocation than those who carried the common alleles (P = 0.03-0.009). In previously study, five haplotypes (GCAA, TTGA, TCGG, TCAA and others) were constructed. The frequencies of these five haplotypes in the Korean population (N = 642), African-American (N = 50) and Caucasian (N = 50) were: 0.495, 0.14, 0.44 (ht1), 0.346, 0.02, 0.23 (ht2), 0.083, 0.17, 0.23 (ht3), 0.07, 0.6, 0.09 (ht4) and 0.006, 0.07, 0.01 (others) in Korean, African-American and Caucasian, respectively. Significant differences in the frequencies of the SNPs and haplotypes were observed among the three ethnic groups. The linkage disequilibrium coefficients (|D'|) and r2 among the SNPs were calculated for all of the study subjects. Strong LDs were noted between SNPs (|D'| > 0.97) in Korean. Complete LDs were observed between SNPs (c.-819 G>T, c.2078 C>T and c.2534 A>G) in Caucasian (|D'| > 0.90). In African-American, between SNPs (c.2534 A>G and c.2545+297A>G) were observed complete LDs (|D'| > 0.92) [20]. Subjects with the ht2 haplotype, which is composed of the rare alleles for the three SNPs (TTG), were susceptible to aspirin intolerance. These results suggest that sequence variants on the promoter (c.-819G>T) of CysLTR2 may affect the efficiency of its transcription with tight linkage to 3'-UTR variations or that the SNPs themselves on 3'-UTR may affect the stability of its mRNA [20]. The functional effects of these SNPs on transcription should be identified. Here, we investigated the genetic effect of the promoter and the 3'-UTR polymorphisms of CysLTR2 at the transcriptional and translational levels of the gene.
###end p 11
###begin title 12
Results
###end title 12
###begin title 13
Flow cytometric analysis of CysLTR2 expression between haplotypes 1 and 2
###end title 13
###begin p 14
###xml 183 186 183 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ht1</italic>
###xml 186 189 186 189 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 219 222 219 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ht2</italic>
###xml 222 225 222 225 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 305 306 305 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 394 396 394 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 508 511 508 511 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ht1</italic>
###xml 511 514 511 514 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 536 539 534 537 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ht2</italic>
###xml 539 542 537 540 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 561 563 557 559 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 578 580 574 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 690 692 686 688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1C</xref>
###xml 786 789 782 785 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ht2</italic>
###xml 789 793 785 789 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 814 817 810 813 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ht1</italic>
###xml 817 821 813 817 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 855 857 847 849 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 996 1004 988 996 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CysLTR2 </italic>
To investigate the effect of the SNPs on the production of CysLTR2 protein in the B cell lines, we measured CysLTR2 protein levels on the surface of B cell lines for ht1 homozygotes (ht1+/+, N = 8) and ht2 homozygotes (ht2+/+, N = 9) using immunofluorescence staining and flow cytometric analysis (Figure 1). Approximately 50% of EBV-infected B cells expressed CysLTR2 on their surface (Figure 1A). The positive rate of CysLTR2 on the B cell lines was not significantly different between the two haplotypes (ht1+/+; 46.96 +/- 5.10% vs. ht2+/+; 48.26 +/- 7.36%, P > 0.05; Figure 1B). The amount of CysLTR2 protein among CysLTR2 positive B cells, however, was significantly different (Figure 1C). The mean fluorescence intensity was significantly higher in B cells of the subjects having ht2+/+ than in those having ht1+/+ (5.07 +/- 0.21 vs. 3.90 +/- 0.45, P = 0.04). These results indicate that single nucleotide polymorphisms on the promoter or 3'-UTR region may affect protein expression of the CysLTR2 gene.
###end p 14
###begin p 15
###xml 95 98 95 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ht1</italic>
###xml 98 101 98 101 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 103 107 103 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GCAA</italic>
###xml 109 110 109 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 113 119 113 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">819G&gt;T</italic>
###xml 121 130 121 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c.2078C&gt;T</italic>
###xml 132 142 132 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c.2534A&gt;G </italic>
###xml 148 159 148 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2545+297A&gt;G</italic>
###xml 189 192 189 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ht2</italic>
###xml 192 195 192 195 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 197 201 197 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TTGG</italic>
###xml 0 202 0 202 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Flow cytometric analysis of CysLTR2 expression on B cell lines between haplotype 1 homozygote (<italic>ht1</italic><sup>+/+</sup>, <italic>GCAA</italic>: <italic>c</italic>.--<italic>819G&gt;T</italic>, <italic>c.2078C&gt;T</italic>, <italic>c.2534A&gt;G </italic>and c.<italic>2545+297A&gt;G</italic>) and haplotype 2 homozygote (<italic>ht2</italic><sup>+/+</sup>, <italic>TTGG</italic>)</bold>
###xml 404 411 404 411 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Methods</italic>
###xml 554 557 554 557 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ht1</italic>
###xml 557 561 557 561 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 562 564 562 564 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 572 575 572 575 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ht2</italic>
###xml 575 579 575 579 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 580 582 580 582 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 802 804 802 804 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 846 847 846 847 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U</italic>
###xml 334 339 <span type="species:ncbi:9606">human</span>
Flow cytometric analysis of CysLTR2 expression on B cell lines between haplotype 1 homozygote (ht1+/+, GCAA: c.--819G>T, c.2078C>T, c.2534A>G and c.2545+297A>G) and haplotype 2 homozygote (ht2+/+, TTGG). (A) Histogram of CysLTR2 protein expression on the EBV-infected B cell line. Immunofluorescence staining was performed using anti-human CysLTR2 Ab and FITC-conjugated secondary Ab as described in the Methods. The histogram is a representative of 17 independent experiments. (B) Ratio of CysLTR2 positive cells of the EBV-infected B cell lines having ht1+/+ (n = 8) or ht2+/+ (n = 9). (C) Mean fluorescence intensity of CysLTR2 expression of the same B cell lines. The ratio of mean FL1 channel values was determined as the FL1 level of CysLTR2 staining to that of isotype-matched control staining. P values were calculated by a Mann--Whitney U-test.
###end p 15
###begin title 16
###xml 33 41 33 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CysLTR2 </italic>
Comparison of mRNA levels of the CysLTR2 gene between haplotypes 1 and 2
###end title 16
###begin p 17
###xml 83 91 83 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CysLTR2 </italic>
###xml 152 155 152 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ht1</italic>
###xml 155 158 155 158 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 162 165 162 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ht2</italic>
###xml 165 169 165 169 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 399 402 399 402 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ht2</italic>
###xml 402 406 402 406 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 418 421 418 421 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ht1</italic>
###xml 421 425 421 425 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 433 436 433 436 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P &gt;</italic>
###xml 449 451 449 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
###xml 517 525 517 525 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CysLTR2 </italic>
###xml 557 560 557 560 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ht2</italic>
###xml 560 564 560 564 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 584 587 584 587 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ht1</italic>
###xml 587 591 587 591 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 599 601 599 601 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 617 619 617 619 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 680 688 680 688 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CysLTR2 </italic>
To investigate the genetic effect of these polymorphisms on the mRNA expression of CysLTR2 in B cell lines, we measured the CysLTR2 mRNA levels between ht1+/+and ht2+/+ by RT-PCR. Semi-quantitation of CysLTR2 mRNA expression was measured by the intensity of CysLTR2 RT-PCR product corrected by the intensity of GAPDH. The expression level of CysLTR2 mRNA in unstimulated B cell lines was similar in ht2+/+ (N = 6) and ht1+/+ (N = 6, P >0.05; Figure 2A); however, PMA/ionomycin markedly induced mRNA expression of the CysLTR2 gene in EBV-infected B cells of ht2+/+ (N = 6) relative to ht1+/+ (N = 6, P = 0.016; Figure 2B). These results indicate that the protein expression of the CysLTR2 gene may be regulated at transcriptional levels.
###end p 17
###begin p 18
###xml 27 30 27 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ht1</italic>
###xml 30 34 30 34 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 37 40 37 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ht2</italic>
###xml 40 44 40 44 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 0 69 0 69 <bold xmlns:xlink="http://www.w3.org/1999/xlink">CysLTR2 mRNA expression of <italic>ht1</italic><sup>+/+ </sup>or <italic>ht2</italic><sup>+/+ </sup>EBV-infected B cell lines</bold>
###xml 312 315 311 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ht1</italic>
###xml 315 318 314 317 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 319 321 318 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 330 333 329 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ht2</italic>
###xml 333 337 332 336 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 338 340 337 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 409 411 406 408 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 451 452 448 449 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U</italic>
###xml 494 497 491 494 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ht1</italic>
###xml 497 501 494 498 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 504 507 501 504 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ht2</italic>
###xml 507 511 504 508 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 532 534 524 526 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 637 640 629 632 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ht2</italic>
###xml 640 644 632 636 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
CysLTR2 mRNA expression of ht1+/+ or ht2+/+ EBV-infected B cell lines. After B cell lines were cultured with or without PMA (10 ng/ml)/ionomycin (2 muM) for 24 h, the mRNA expression of CysLTR2 was analyzed by RT--PCR. (A) The intensities of PCR products were measured using a densitometer, and compared between ht1+/+(n = 6) and ht2+/+ (n = 6) B cell lines. (B) The data are presented as the mean +/- SEM. * P < 0.05 calculated using a Mann--Whitney U-test for comparing PMA/ionomycin-treated ht1+/+ or ht2+/+ B cell lines. dagger P < 0.01 calculated using Wilcoxon's signed-ranks test for comparing PMA/ionomycin-treated and untreated ht2+/+ B cell lines.
###end p 18
###begin title 19
###xml 56 64 56 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CysLTR2 </italic>
###xml 73 83 73 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c.-819 T&gt;G</italic>
Comparison of promoter activity between T and G type of CysLTR2 promoter c.-819 T>G
###end title 19
###begin p 20
###xml 20 28 20 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CysLTR2 </italic>
###xml 249 250 249 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 252 257 252 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink">819T </italic>
###xml 260 262 260 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G </italic>
###xml 311 318 311 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Methods</italic>
Because the SNPs of CysLTR2 haplotype 1 and 2 are located on the promoter region and on the 3'-UTR region, we investigated the individual effect of these two SNPs on CysLTR2 mRNA expression. First, we compared the activities of promoters possessing c.-819T or G by luciferase reporter assay as described in the Methods.
###end p 20
###begin p 21
###xml 80 82 80 82 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 89 97 89 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CysLTR2 </italic>
###xml 213 214 213 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 216 221 216 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">819G </italic>
###xml 225 227 225 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">T </italic>
###xml 456 458 453 455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
###xml 460 461 457 458 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 463 467 460 464 <italic xmlns:xlink="http://www.w3.org/1999/xlink">819G</italic>
###xml 488 489 483 484 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 491 495 486 490 <italic xmlns:xlink="http://www.w3.org/1999/xlink">819T</italic>
###xml 513 515 506 508 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 604 605 597 598 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 607 612 600 605 <italic xmlns:xlink="http://www.w3.org/1999/xlink">819T </italic>
###xml 627 629 620 622 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G </italic>
###xml 679 680 672 673 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 682 687 675 680 <italic xmlns:xlink="http://www.w3.org/1999/xlink">819T </italic>
###xml 699 707 692 700 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CysLTR2 </italic>
###xml 758 759 751 752 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 761 766 754 759 <italic xmlns:xlink="http://www.w3.org/1999/xlink">819G </italic>
###xml 821 823 810 812 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 878 886 867 875 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CysLTR2 </italic>
###xml 985 989 974 978 <italic xmlns:xlink="http://www.w3.org/1999/xlink">819 </italic>
Due to 293 T cells expressing CysLTR2 mRNA by PMA/ionomycin stimulation (Figure 3A), the CysLTR2 promoter-luciferase constructs were transfected into the cells and the differences in luciferase activities between c.-819G and T were analyzed. Luciferase activity was normalized by beta-galactosidase activity co-transfected as an internal control. In the absence of stimulation, no difference was observed in luciferase activities between genotypes (Figure 3B, c.-819G; 41.83 +/- 6.01 vs. c.-819T; 38.12 +/- 2.28, P > 0.05). However, PMA/ionomycin stimulation significantly induced luciferase activity in c.-819T but not in the G type. As a result, the luciferase activity of the c.-819T type of the CysLTR2 promoter was significantly higher than that of the c.-819G type (60.79 +/- 4.21 vs. 35.30 +/- 2.70, respectively, P = 0.002). These data suggest that transcription of the CysLTR2 gene may be differently regulated when stimulated according to the nucleotide polymorphism at the -819 locus on the promoter.
###end p 21
###begin p 22
###xml 10 11 10 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 14 20 14 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">819T&gt;G</italic>
###xml 44 52 44 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CysLTR2 </italic>
###xml 0 56 0 56 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Promoter (<italic>c</italic>.--<italic>819T&gt;G</italic>) activity of the human <italic>CysLTR2 </italic>gene</bold>
###xml 172 180 172 180 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CysLTR2 </italic>
###xml 430 431 427 428 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 811 813 800 802 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 853 854 842 843 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U</italic>
###xml 926 927 915 916 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 930 935 919 924 <italic xmlns:xlink="http://www.w3.org/1999/xlink">819G </italic>
###xml 939 940 928 929 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 943 948 932 937 <italic xmlns:xlink="http://www.w3.org/1999/xlink">819T </italic>
###xml 965 967 949 951 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1095 1102 1079 1086 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c.819T </italic>
###xml 38 43 <span type="species:ncbi:9606">human</span>
Promoter (c.--819T>G) activity of the human CysLTR2 gene. The 293 T cells expressed CysLTR2, which increased with 24 h PMA/ionomycin stimulation (A) The promoter region of CysLTR2 having c.--819T or c.--819G was inserted into the pGL3 basic vector and the constructs and beta-galactosidase expression vector were co-transfected into 293 T cells by lipofection. Twenty-four hours after transfection, the transfected cells (2.5 x 105/ml) were stimulated with 10 ng/ml of PMA and 2 mM of ionomycin for 24 h. Luciferase activities were measure by luminometer and normalized by beta-galactosidase activities as internal controls. (B) The data are presented as the mean +/- SEM of normalized luciferase activities (the ratio of luciferase activities to beta-galactosidase activities) of six independent experiments. *P < 0.01 calculated using a Mann--Whitney U-test for comparing luciferase activities between PMA/ionomycin-treated c.--819G and c.--819T promoter. dagger P < 0.05 calculated using Wilcoxon's signed-ranks test for comparing luciferase activities of PMA/ionomycin-treated and untreated c.819T promoter.
###end p 22
###begin title 23
###xml 69 86 69 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CysLTR2 c.-819T&gt;G</italic>
Nuclear factor binding site on the region of the promoter containing CysLTR2 c.-819T>G
###end title 23
###begin p 24
###xml 48 56 48 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CysLTR2 </italic>
###xml 57 58 57 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 60 81 60 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink">819G&gt;T) provided the </italic>
###xml 263 272 263 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CysLTR2 c</italic>
###xml 274 279 274 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink">819T </italic>
###xml 287 289 287 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4C</xref>
###xml 368 369 368 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 371 400 371 400 <italic xmlns:xlink="http://www.w3.org/1999/xlink">819T than with the probe for </italic>
###xml 404 405 404 405 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 407 416 407 416 <italic xmlns:xlink="http://www.w3.org/1999/xlink">819G and </italic>
###xml 676 708 676 708 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CysLTR2 promoter region around c</italic>
###xml 710 759 710 759 <italic xmlns:xlink="http://www.w3.org/1999/xlink">819T may be the binding site for a transcription </italic>
###xml 878 879 878 879 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 881 888 881 888 <italic xmlns:xlink="http://www.w3.org/1999/xlink">819T&gt;G </italic>
###xml 926 928 926 928 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4A</xref>
###xml 933 935 933 935 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4B</xref>
###xml 1002 1007 <span type="species:ncbi:9606">human</span>
To confirm whether the locus on the promoter of CysLTR2 (c.-819G>T) provided the binding sites for a transcription factor, gel shift assays were performed using the nuclear extract from EBV-infected B cells. DNA-protein complexes were detected with the probe for CysLTR2 c.-819T (Figure 4C). The intensity of this complex was higher when hybridized with the probe for c.-819T than with the probe for the c.-819G and decreased through competition with the unlabeled probe of each type. Nuclear extract from the PMA/ionomycin-stimulated B cell lines showed stronger DNA-protein binding affinity in the T type of probe than the unstimulated B cell lines. This indicates that the CysLTR2 promoter region around c.-819T may be the binding site for a transcription factor. Since a TFSEARCH search revealed putative binding sites for several candidate transcription factors around the c.-819T>G allele, such as HFH-2 and SRY (Figure 4A and 4B), we performed a supershift assay for SRY and Foxd3, which is the human homolog of HFH-2. However, neither HFH-2 nor SRY showed the supershift in EMSA (data not shown).
###end p 24
###begin p 25
###xml 24 33 24 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CysLTR2 c</italic>
###xml 36 40 36 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">819 </italic>
###xml 0 79 0 79 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Gel shift assay for SNP <italic>CysLTR2 c</italic>.--<italic>819 </italic>using nuclear extract from B cell lines</bold>
###xml 127 136 127 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c.--819T </italic>
###xml 144 146 144 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G </italic>
###xml 359 368 359 368 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c.--819G </italic>
###xml 371 373 371 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink">T </italic>
###xml 608 610 607 609 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 690 697 689 696 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Methods</italic>
Gel shift assay for SNP CysLTR2 c.--819 using nuclear extract from B cell lines. Putative transcription factor binding site of c.--819T (A) and G type (B) are indicated by underlines (TFSEARCH Searching Transcriptional Factor Binding Sites V1.3). Gel shift assays were performed using nuclear extracts of EBV-infected B cell lines and dsDNA probes possessing c.--819G or T (C). One million cells per milliliter of EBV-infected B cell lines established from asthmatics were cultured for 24 h with or without 10 ng/ml of PMA and 2 muM of ionomycin. The nuclear extracts of B cell lines were incubated with the 32P-labeled probes, the sequences of which included each genotype of c.--819 (see Methods). To identify specific binding complexes, nuclear extract from B cell lines was preincubated with the unlabeled probe 10 min before the addition of the labeled probe. The open arrow shows the specific DNA--protein complexes and the filled arrow indicates the free unbound probe. Arrowheads denote nonspecific DNA--protein complexes. These data are representative of six independent experiments.
###end p 25
###begin title 26
###xml 59 67 59 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CysLTR2 </italic>
###xml 75 84 75 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c.2078C&gt;T</italic>
Comparison of 3'-UTR activity between C and T types of the CysLTR2 3'- UTR c.2078C>T
###end title 26
###begin p 27
###xml 58 68 58 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c.2078C&gt;T </italic>
###xml 174 182 174 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c.2078C </italic>
###xml 185 188 185 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink">T) </italic>
###xml 196 204 196 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CysLTR2 </italic>
###xml 270 272 270 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5A</xref>
###xml 314 322 314 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CysLTR2 </italic>
###xml 585 594 585 594 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c.2078T) </italic>
###xml 653 661 653 661 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c.2078C </italic>
###xml 679 681 679 681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5B</xref>
###xml 730 732 726 728 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 784 792 780 788 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c.2078T </italic>
###xml 839 846 835 842 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c.2078C</italic>
To evaluate the effect due to sequence variance of 3'-UTR c.2078C>T on CysLTR2 protein expression, the fluorescence intensity of 293 T cell lines transfected with each type (c.2078C or T) of EGFP-CysLTR2 3'-UTR fusion construct was analyzed using flow cytometry (Figure 5A). The EGFP expression levels of the EGFP-CysLTR2 3'-UTR fusion constructs were analyzed as the mean fluorescence intensity of EGFP of all cells analyzed. On flow cytometry analysis, side scatter and forward scatter were not different between the two cell types. The relative EGFP expression level of the 3'-UTR (c.2078T) fusion construct was significantly higher than that of the c.2078C construct (Figure 5B; 0.96 +/- 0.07 vs. 0.48 +/- 0.06, respectively, P = 0.002), indicating that the mRNA stability of the c.2078T type of CysLTR2 3'-UTR was higher than that of c.2078C.
###end p 27
###begin p 28
###xml 53 61 53 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CysLTR2 </italic>
###xml 0 99 0 99 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Flow cytometric analysis of the effects of the human <italic>CysLTR2 </italic>gene 3'-UTR on EGFP protein expression</bold>
###xml 145 147 145 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C </italic>
###xml 150 151 150 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink">T</italic>
###xml 248 255 248 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Methods</italic>
###xml 720 722 715 717 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 765 766 760 761 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U</italic>
###xml 47 52 <span type="species:ncbi:9606">human</span>
###xml 211 215 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
Flow cytometric analysis of the effects of the human CysLTR2 gene 3'-UTR on EGFP protein expression. The 3'-UTR region possessing each genotype (C or T) on c.2078 was inserted between the EGFP coding region and SV40 poly A site as described in the Methods. After each construct was co-transfected with the beta-galactosidase expression vector as an internal control into 293 T cell lines, the expression levels of the EGFP protein were measured using a flow cytometer (A) and the fluorescence intensity of each construct was compared (B). The data are presented as the mean +/- SEM of relative FL1 values (the ratio of EGFP--CysLTR2 3'-UTR fusion constructs to naive pEGFP-N1 vector) of six independent experiments. The P value was calculated using a Mann--Whitney U-test.
###end p 28
###begin title 29
Discussion
###end title 29
###begin p 30
###xml 59 60 59 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 62 68 62 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">819G&gt;T</italic>
###xml 77 85 77 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CysLTR2 </italic>
###xml 174 185 174 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c.2078C&gt;T) </italic>
###xml 251 259 251 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CysLTR2 </italic>
###xml 409 410 409 410 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 412 418 412 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink">819G&gt;T</italic>
###xml 420 429 420 429 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c.2078C&gt;T</italic>
###xml 435 444 435 444 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c.2534A&gt;G</italic>
###xml 450 454 450 454 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ht1 </italic>
###xml 455 456 455 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 457 458 457 458 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 459 460 459 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 461 462 461 462 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 465 469 465 469 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ht2 </italic>
###xml 470 471 470 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink">T</italic>
###xml 472 473 472 473 <italic xmlns:xlink="http://www.w3.org/1999/xlink">T</italic>
###xml 474 475 474 475 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G</italic>
###xml 476 477 476 477 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 524 526 524 526 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 570 572 570 572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 664 672 664 672 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CysLTR2 </italic>
###xml 726 734 726 734 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CysLTR2 </italic>
###xml 807 809 807 809 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 859 861 859 861 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 862 864 862 864 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 880 882 880 882 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 900 902 900 902 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 1105 1107 1105 1107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1155 1158 1155 1158 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ht2</italic>
###xml 1158 1162 1158 1162 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 1256 1259 1256 1259 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ht1</italic>
###xml 1259 1262 1259 1262 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 1299 1300 1299 1300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 1305 1306 1305 1306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 1417 1425 1417 1425 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CysLTR2 </italic>
###xml 1456 1460 1456 1460 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ht2 </italic>
###xml 1539 1543 1539 1543 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ht1 </italic>
###xml 1584 1586 1584 1586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1779 1787 1779 1787 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CysLTR2 </italic>
###xml 1849 1851 1849 1851 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 1867 1869 1867 1869 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 1887 1889 1887 1889 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
We demonstrated that the sequence variant on the promoter (c.-819G>T) of the CysLTR2 gene affects the efficiency of its transcription and the sequence variant on the 3'-UTR (c.2078C>T) modulates mRNA degradation, resulting in different expressions of CysLTR2 protein according to the gene genotypes. We previously identified three novel SNPs in the promoter and 3'-untranslated region of CysLTR2. Three SNPs (c.-819G>T, c.2078C>T, and c.2534A>G) and ht1 [G-C-A-A], ht2 [T-T-G-A] were strongly associated with the drop in FEV1 induced by aspirin challenge in asthmatics [20]. To identify the functional effects of these SNPs on transcription and translation of the CysLTR2 gene, we first measured the protein expression of the CysLTR2 gene. CysLTR2 is known to be expressed by lung interstitial macrophages [10], pulmonary vascular smooth muscle, endothelium [11-13], eosinophils [14] and mast cells [15]. These cells are difficult to obtain and maintain from our asthmatics subjects, so we used immortalized B cells induced by EB virus from subjects whose genotypes had been analyzed in a previous study [20]. We demonstrated that the B cell lines having ht2+/+ had a higher translational and transcriptional expression levels of CysLTR2 than those having ht1+/+, especially when stimulated (Figure 1 and 2). These results indicate that the genetic differences affect the amount of protein and mRNA expression in the CysLTR2 gene. In our previous studies, ht2 homozygote asthmatics showed the highest responses to aspirin challenge, while ht1 homozygotes showed the lowest responses [20]. Taken together, these data suggest that the greater response to aspirin challenge in asthmatics may be due to higher expression of CysLTR2 protein on the B cells and presumably on the other CysLTR2 gene-expressing cells, such as lung interstitial macrophages [10], eosinophils [14] and mast cells [15].
###end p 30
###begin p 31
###xml 63 64 63 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 66 72 66 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">819G&gt;T</italic>
###xml 74 84 74 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c.2078C&gt;T </italic>
###xml 88 97 88 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c.2534A&gt;G</italic>
###xml 236 237 236 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 239 245 239 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink">819G&gt;T</italic>
###xml 254 262 254 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CysLTR2 </italic>
###xml 406 414 406 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CysLTR2 </italic>
###xml 441 443 441 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink">T </italic>
###xml 483 485 483 485 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G </italic>
###xml 569 577 569 577 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CysLTR2 </italic>
###xml 601 602 601 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 639 640 639 640 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 642 648 642 648 <italic xmlns:xlink="http://www.w3.org/1999/xlink">819G&gt;T</italic>
###xml 712 713 712 713 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 779 780 779 780 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 782 797 782 797 <italic xmlns:xlink="http://www.w3.org/1999/xlink">819T than for c</italic>
###xml 799 804 799 804 <italic xmlns:xlink="http://www.w3.org/1999/xlink">819G </italic>
###xml 854 855 854 855 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 956 957 956 957 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 959 976 959 976 <italic xmlns:xlink="http://www.w3.org/1999/xlink">819G&gt;T locus and </italic>
###xml 983 991 983 991 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CysLTR2 </italic>
###xml 1142 1179 1142 1179 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CysLTR2 gene expression. With c.-819T</italic>
###xml 1288 1289 1288 1289 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 1291 1309 1291 1309 <italic xmlns:xlink="http://www.w3.org/1999/xlink">819G, which would </italic>
###xml 1318 1358 1318 1358 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CysLTR2 gene expression. We performed a </italic>
###xml 1440 1445 <span type="species:ncbi:9606">human</span>
Next, we assessed the regulating mechanisms of the three SNPs (c.-819G>T, c.2078C>T and c.2534A>G) on CysLTR2 protein expression using promoter activity assays and 3'-UTR function analysis because the sequence variants on the promoter (c.-819G>T) of the CysLTR2 gene may affect the efficiency of its transcription and the SNPs on the 3'-UTR may affect the stability of its mRNA. Luciferase activity of the CysLTR2 promoter was higher in the T type transfected 293T cells than in the G type, which indicates that the sequence variants on the promoter are regulators for CysLTR2 gene expression (Figure 3). The genetic role of the promoter (c.-819G>T) was demonstrated by the nuclear protein binding assay (Figure 4). The binding affinity of this DNA-binding factor was higher for c.-819T than for c.-819G with or without PMA/ionophore stimulation (Figure 4). In the steady state, this DNA-binding factor may bind constitutively to the promoter close to the c.-819G>T locus and induce CysLTR2 gene expression. Moreover, PMA/ionophore-stimulated signaling may cause an increase in this binding factor on the promoter, which would induce greater CysLTR2 gene expression. With c.-819T, PMA/ionophore-induced signaling may cause higher-level binding of the DNA-binding factor than it does with c.-819G, which would increase CysLTR2 gene expression. We performed a supershift assay for the candidate factors: SRY and HFH-2. Neither SRY nor FoxD3 (human homolog of HFH2) antibodies showed supershifts in EMSA. The nature of the putative DNA-binding factor therefore remains to be clarified.
###end p 31
###begin p 32
###xml 58 68 58 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c.2078C&gt;T </italic>
###xml 72 81 72 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c.2534A&gt;G</italic>
###xml 86 94 86 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CysLTR2 </italic>
###xml 143 153 143 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c.2534A&gt;G </italic>
###xml 305 313 305 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c.2078T </italic>
###xml 356 364 356 364 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c.2078C </italic>
###xml 372 373 372 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 430 438 430 438 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CysLTR2 </italic>
###xml 604 628 604 628 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CysLTR2 gene expression </italic>
###xml 825 829 825 829 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ht1 </italic>
###xml 859 863 859 863 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ht2 </italic>
###xml 1011 1015 1011 1015 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ht2 </italic>
###xml 1053 1056 1053 1056 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ht1</italic>
###xml 1320 1322 1320 1322 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 1332 1334 1332 1334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 1335 1337 1335 1337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 1384 1386 1384 1386 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 1771 1773 1771 1773 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 1849 1851 1849 1851 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 1987 1995 1987 1995 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 1831 1836 <span type="species:ncbi:9606">human</span>
In the evaluation of the sequence variance of the 3'-UTR (c.2078C>T and c.2534A>G) on CysLTR2 gene expression, the former was chosen since the c.2534A>G is located 124 bp downstream from the polyadenylation site and would not be present in mature mRNA. The expression level of fluorescence containing the c.2078T type was significantly higher than that of c.2078C (Figure 5). This indicates that mRNA degradation of the T type of CysLTR2 3'-UTR was much slower than that of the C type. Based on the results of our promoter and 3'-UTR functional study, the sequence variance of the two loci may influence CysLTR2 gene expression cooperatively. To validate the results of our promoter and 3'-UTR functional study, we performed the additional experiment using the vectors containing both promoter and 3'-UTR regions of CysLTR2. Ht1 (c. -819 G and c. 2078 C) and Ht2 (c. -819 T and c. 2078 T) were inserted into pGL3-basic luciferase reporter system, respectively. The expression level of luciferase containing the ht2 was significantly higher than that of ht1, especially when stimulated with PMA plus ionomycin (data not shown). These results indicate that the combined genetic differences affect the amount of protein and mRNA expression in CysLTR2 gene. In contrast to the extensive studies on the functions of the CysLT1 receptor [21,22], the functional characterization of the CysLT2 receptor has been limited because of a lack of specific competitive antagonists. Recent experimental studies have demonstrated unanticipated functions for the cysLTs, acting nonredundantly through CysLTR2. CysLTR2, but not CystLTR1, is the receptor responsible for mediating the contribution of the CysLTs to experimental bleomycin-induced chronic pulmonary inflammation and fibrosis [23], and for the production of IL-8 by IL-4-primed cultured human mast cells [24]. However, the impact of the receptor has not been revealed in chronic inflammatory airway diseases such as asthma. In particular, any in vivo role for the CysLTR2 receptor remains unknown. To the best of our knowledge, our study is the first to clearly demonstrate the genetic relationship between the CysLTR2 receptor nucleotide polymorphism and aspirin hypersensitivity in asthmatics at the level of gene function.
###end p 32
###begin title 33
Conclusion
###end title 33
###begin p 34
###xml 59 67 59 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CysLTR2 </italic>
The sequence variants on the promoter and on the 3'-UTR of CysLTR2 affect the efficiency of its transcription and the stability of its mRNA, resulting in the alteration of protein expression of CysLTR2. This change causes a certain number of asthmatics to be susceptible to aspirin hypersensitity. This functional evidence may have genetic value as a diagnostic biomarker and could provide fundamental information for the development of therapeutic strategies.
###end p 34
###begin title 35
Methods
###end title 35
###begin title 36
EV virus-infected B cell culture
###end title 36
###begin p 37
###xml 99 103 99 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GCAA</italic>
###xml 105 106 105 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 108 114 108 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink">819G&gt;T</italic>
###xml 116 137 116 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c.2078C&gt;T, c.2534A&gt;G </italic>
###xml 143 154 143 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2545+297A&gt;G</italic>
###xml 198 202 198 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TTGG</italic>
###xml 715 716 708 709 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 760 762 753 755 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4 </sup>
Venous whole blood was obtained from asthmatics having the haplotype 1 (common allele homozygotes (GCAA: c.-819G>T, c.2078C>T, c.2534A>G and c.2545+297A>G) and haplotype 2 (rare allele homozygotes (TTGG)) and peripheral blood mononuclear cells (PBMC) were separated using discontinuous Histopaque gradients solution (Sigma, St. Louis, MO). PBMC were infected with B95-8 supernatant and incubated with 0.5 mug/ml of cyclosporine A (Sigma) for 3 weeks. Cells were cultured in RPMI 1640 (Invitrogen Life Technologies, Carlsbad, CA) supplemented with L-glutamine (2 mM), HEPES (25 mM), and 10% FBS (Invitrogen Life Technologies). All cell lines were maintained in culture at 37degreesC in an atmosphere containing 5% CO2. Cells were reseeded at a density of 5 x 104 cells/ml every 3-4 days. This study was performed with the approval of the Ethics Committee of the Soonchunhyang University Hospital and informed written consent was obtained from all the study subjects.
###end p 37
###begin title 38
Flow cytometry analysis of CysLTR2 protein expression
###end title 38
###begin p 39
###xml 483 487 <span type="species:ncbi:9925">goat</span>
###xml 493 499 <span type="species:ncbi:9986">rabbit</span>
###xml 609 614 <span type="species:ncbi:10090">mouse</span>
The expression of CysLTR2 in B cell lines was assessed with the use of a polyclonal anti-CysLTR2 antibody (Cayman Chemicals, Ann Arbor, MI) directed against amino acids 1-18 of the N-terminal portion of the receptor. For flow cytometry studies, B cell lines were washed twice with PBS and labeled for 30 min at 4degreesC with anti-CysLTR2 antibody (or irrelevant antibody for control). Cells were then washed twice with PBS and incubated for 30 min at 4degreesC with FITC-conjugated goat anti-rabbit IgG (BD Pharmingentrade mark; BD Biosciences, San Diego, CA). As an isotype-matched control, FITC-conjugated mouse IgG1kappa (BD Biosciences) was similarly treated. Finally, cells were washed again and resuspended in PBS. An analysis of fluorescence staining was performed with a FACSCalibur flow cytometer and Cell Quest Software (Counter Corporation, Miami, FL). The levels of CysLTR2 expression were determined as the percentage of positive staining and the ratio of mean FL1 channel values of CysLTR2 stain. The percentage of positive staining was measured as the cells showing fluorescence above that of the control antibody. The ratio of mean FL1 channel values was determined as the FL1 level of CysLTR2 stain to that of the isotype-matched control stain.
###end p 39
###begin title 40
Semi-quantitation of mRNA expression using reverse transcriptase polymerase chain reaction
###end title 40
###begin p 41
###xml 880 881 835 836 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 887 892 <span type="species:ncbi:9606">human</span>
Total RNA was extracted using TRI Reagent (guanidium thiocyanate-phenol mixture; Molecular Research Center, Inc., Cincinnati, OH) and chloroform. Possible DNA contamination was eliminated by treatment with 1 mul of RNase-free DNase I (10,000 U/ml; Stratagene, La Jolla, CA) for 15 min at 37degreesC. The reaction was stopped with 0.5 mul of 2 mM EDTA. DNase I-treated RNA was heated at 65degreesC for 5 min with 1 mul of oligo deoxythymidine-15 primer (500 mug/ml) and 10 mM dNTP mix, then quickly chilled on ice. After centrifugation, DNase I-treated RNA were incubated at 42degreesC for 2 min with 0.1 mM DTT and 1 mul of SuperScript IItrade mark RT (200 U/mul; Invitrogen Life Technologies) at 42degreesC for 50 min, and then heat inactivated at 70degreesC for 15 min. Following reverse transcription (RT), cDNA was aliquoted into tubes containing specific primer pairs (Table 1) for human CysLTR2 and GAPDH genes to amplify into 706-bp and 300-bp PCR products, respectively. Amplification was performed on a thermocycler for 30 cycles (one cycle: 1 min at 95degreesC, 1 min at 55degreesC, and 1 min at 72degreesC) with the initial denaturation at 95degreesC for 5 min and a final extension at 72degreesC for 7 min. Amplified PCR products were electrophoresed on a 1% agarose gel and visualized by ethidium bromide staining.
###end p 41
###begin p 42
Primer sequences used in this study
###end p 42
###begin p 43
###xml 119 125 119 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nhe I </italic>
###xml 135 141 135 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xho I </italic>
Underlined nucleotide sequences are added to the 5' end of oligonucleotide primer for cloning. These cloning sites are Nhe I (GCTAGC), Xho I (CTCGAG), and Not I (GCGGCCGC), and they are preceded by A and T residues at random
###end p 43
###begin title 44
###xml 29 38 29 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c.-819T&gt;G</italic>
###xml 72 81 72 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c.2078C&gt;T</italic>
Preparation of the promoter (c.-819T>G)-luciferase and the EGFP-3'-UTR (c.2078C>T) reporter constructs
###end title 44
###begin p 45
###xml 31 39 31 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CysLTR2 </italic>
###xml 173 181 173 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CysLTR2 </italic>
###xml 544 548 544 548 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NheI</italic>
###xml 549 554 549 554 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XhoI </italic>
###xml 558 562 558 562 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NotI</italic>
###xml 563 568 563 568 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NotI </italic>
###xml 623 624 623 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 730 735 730 735 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NheI </italic>
###xml 739 744 739 744 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XhoI </italic>
###xml 816 821 816 821 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NheI </italic>
###xml 825 830 825 830 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XhoI </italic>
###xml 940 945 940 945 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NotI </italic>
The promoter and UTR region of CysLTR2 were amplified by PCR. Primary PCR products were amplified using the genomic DNA of allele-matched B cell lines as templates from the CysLTR2 promoter (1520-bp fragment, from -1342 to +178) and UTR (2287 bp fragment, from +501 to +2787) sequence. The primary PCR reaction mixture was diluted and used as a template for a nested PCR using the nested primer. The secondary PCR primer for the promoter (1027-bp fragments, from -1008 to -4) and UTR (1395-bp fragments, from +1042 to +2410) region contained a NheI-XhoI and NotI-NotI restriction site. The primers used are listed in Table 1. The amplified PCR product was cloned into a pGEM-T easy vector (Promega, Madison, WI) and digested with NheI and XhoI (New England Biolabs, Beverly, MA). The fragment was subcloned into the NheI and XhoI sites of a promoterless luciferase reporter pGL3-Basic vector (Promega). The UTR fragment was cloned into the NotI site of an enhanced green fluorescent protein (EGFP) expression plasmid, pEGFP-N1 vector (BD Biosciences). Plasmids were isolated using the Qiagen plasmid purification kit (Qiagen, Santa Clarita, CA).
###end p 45
###begin title 46
Transient transfection and assays of luciferase and fluorescence intensity
###end title 46
###begin p 47
###xml 335 336 329 330 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 373 375 367 369 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5 </sup>
###xml 576 584 570 578 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CysLTR2 </italic>
###xml 1712 1720 1687 1695 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CysLTR2 </italic>
The 293 T cells were grown in Dulbecco's modified Eagle's medium (Life Technologies, Rockville, MD) with L-glutamine (2 mM), HEPES (25 mM), 10% heat-inactivated FBS (Invitrogen Life Technologies), 100 U/ml penicillin, and 100 ng/ml streptomycin (Life Technologies-BRL, Gaithersburg, MD) at 37degreesC in humidified air containing 5% CO2. One day before transfection, 5 x 105 cells were seeded per well in 2 ml without antibiotics to obtain 90-95% confluence at the time of transfection. The 293 T cells were then transiently transfected with pGL3-promoter or pEGFP-UTR of the CysLTR2 gene using LF2000 (Invitrogen Life Technologies; recommended mug DNA: mul lipofectamine = 1:2) in OptMEM (Life Technologies-BRL) without serum. One microgram of pSV-beta-galactosidase control vector (Promega) was co-transfected to normalize transfection efficiencies. For promoter construct transfection, PMA (10 ng/ml) and ionomycin (2 muM) was added for 24 h after transfection. After 48 h of transfection, cultured cells were washed twice with PBS and solubilized by scraping with 400 mul of reporter lysis buffer (Promega). Cells were centrifuged and the supernatant was stored at -70degreesC. beta-galactosidase activities were assessed by ortho-nitrophenyl-D-galactopyranoside (ONPG) hydrolysis using a beta-Galactosidase Enzyme Assay System Kit (Promega) and total protein was measured using a BCA protein assay kit (Pierce, Rockford, IL). Luciferase activity was measured using the Luciferase Assay System (Promega) by a Turner 20/20 n luminometer (Turner BioSystems, Inc., Sunnyvale, CA) and expressed as relative luciferase activity to that of empty pGL3-basic vector. The expression levels of EGFP with the 3'-UTR of CysLTR2 were assessed by measuring the mean channel values of FL1 in flow cytometry (BD Biosciences) at 48 h after transfections. The relative mean value of FL1 was calculated as described above. The ratio of mean FL1 channel values was determined as the FL1 level of the transfectant stain to that of the isotype-matched control stain.
###end p 47
###begin title 48
Nuclear extract preparation and electrophoretic mobility shift assays (EMSA)
###end title 48
###begin p 49
###xml 67 72 67 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 75 77 75 77 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 268 269 268 269 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1252 1254 1241 1243 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 1891 1895 <span type="species:ncbi:9925">goat</span>
###xml 1901 1906 <span type="species:ncbi:9606">human</span>
###xml 1960 1964 <span type="species:ncbi:9925">goat</span>
###xml 1970 1975 <span type="species:ncbi:9606">human</span>
Nuclear extracts were prepared by the modified method of Schreiber et al. [25]. The PMA and ionomycin stimulated B cell lines and unstimulated B cell lines were harvested after washing twice with HBSS. Cells were washed with buffer A (10 mM HEPES, 15 mM KCl, 2 mM MgCl2, 0.1 mM EDTA, 1 mM DTT, 0.5 mM PMSF, 10 mug/ml leupeptin, 10 mug/ml aprotinin; Calbiochem, La Jolla, CA). The cell pellet was resuspended in buffer B (buffer A containing 0.2% Nonidet P-40) and incubated for 10 min. Nuclei were pelleted by centrifugation and resuspended in buffer C (buffer A containing 0.25 M sucrose). Nuclei were again pelleted, then resuspended in buffer D (50 mM HEPES, 400 mM KCl, 10% glycerol, 0.1 mM EDTA, 1 mM DTT, 0.5 mM PMSF, 10 mug/ml leupeptin, 10 mug/ml aprotinin; Calbiochem) and incubated with shaking for 30 min. All procedures were performed on ice. The mixture was centrifuged, and the supernatant was stored at -70degreesC. DNA-protein binding assays were performed using the Gel Shift Assay System (Promega) following the manufacturer's instructions. Ten-microgram aliquots of nuclear extracts were incubated in 10 mul of total reaction volume containing binding buffer (Promega) for 10 min with or without unlabeled oligonucleotide probe. The 32P-labeled oligonucleotide probe was added to the reaction mixture and then incubated for 20 min. The reaction products were analyzed by electrophoresis in a 4% polyacrylamide gel with 0.5x TBE buffer. Gels were dried and analyzed by autoradiography. The sequences of the oligonucleotide probes used were forward: 5'-TTTTG TTTTG TTGTT [G/T]TTTT TTTTT TTTTT G-3', reverse: 5-CAAAA AAAAA AAAAA [C/A]AACA ACAAA ACAAA A-3. To determine the specificities of the DNA-protein complexes, 1.75 pmol of unlabeled probe was incubated with the nuclear extract for 10 min before the addition of the labeled probe. For the supershift assay, 200 mug of goat anti-human SRY Ab (Santa Cruz Biotechnology, Santa Cruz, CA) or goat anti-human FoxD3 Ab (Santa Cruz Biotechnology) was incubated with the nuclear extract for 30 min before the addition of the labeled probe.
###end p 49
###begin title 50
Statistical analysis
###end title 50
###begin p 51
###xml 256 257 254 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 338 339 336 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U</italic>
Data are expressed as the mean +/- standard error of the mean (SEM). The program SPSS (version 10.0; SPSS Inc., Chicago, IL) was used for all analyses. Differences between independent groups and samples were compared using the nonparametric Kruskal-Wallis H-test for continuous data. If significant differences were found, a Mann-Whitney U-test was applied to compare differences between two samples. Wilcoxon's signed-ranks test was used for two related samples.
###end p 51
###begin title 52
Abbreviations
###end title 52
###begin p 53
###xml 151 152 151 152 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 306 324 <span type="species:ncbi:10376">Epstein-Barr virus</span>
AIA: Aspirin-intolerant asthma; NSAID: non-steroidal anti-inflammatory drugs; CysLT: cysteinyl leukotriene; CysLTR: cysteinyl leukotriene receptor; FEV1: Forced expiratory volume in one second; SNP: Single nucleotide polymorphism; LD: Linkage disequilibrium; PBMC: peripheral blood mononuclear cells; EBV: Epstein-Barr virus; EGFP: Enhanced green fluorescent protein; EMSA: Electrophoretic mobility shift assays; SEM: Standard error of the mean.
###end p 53
###begin title 54
Competing interests
###end title 54
###begin p 55
The authors declare that they have no competing interests.
###end p 55
###begin title 56
Authors' contributions
###end title 56
###begin p 57
JAS performed all the experimental steps, HSC provided experimental assistance, SMP drafted the manuscript, CSP provided analytic support and supervised the project. ASJ, SWP, JSP, STU, GIL, TR, MKK, ISC and IYC provided analytic and data assistance. BLP and HDS supervised the SNP analysis. All authors have read and approved this final manuscript.
###end p 57
###begin title 58
Pre-publication history
###end title 58
###begin p 59
The pre-publication history for this paper can be accessed here:
###end p 59
###begin p 60

###end p 60
###begin title 61
Acknowledgements
###end title 61
###begin p 62
This work was supported by a grant from the Korea Health 21 R&D Project, Ministry of Health, Welfare and Family Affairs, Republic of Korea (A010249). The biospecimens for this study were provided by the Soonchunhyang University Hospital, a member of the National Biobank of Korea.
###end p 62
###begin article-title 63
Concerning the nature of intolerance to aspirin
###end article-title 63
###begin article-title 64
Leukotriene-receptor expression on nasal mucosal inflammatory cells in aspirin-sensitive rhinosinusitis
###end article-title 64
###begin article-title 65
Aspirin-intolerant asthma: role of cyclo-oxygenase enzymes
###end article-title 65
###begin article-title 66
###xml 110 118 <span type="species:ncbi:9606">patients</span>
Relationship of inhibition of prostaglandin biosynthesis by analgesics to asthma attacks in aspirin-sensitive patients
###end article-title 66
###begin article-title 67
The cyclooxygenase theory of aspirin-induced asthma
###end article-title 67
###begin article-title 68
The role of leukotrienes in inflammation
###end article-title 68
###begin article-title 69
Treatment of asthma with drugs modifying the leukotriene pathway
###end article-title 69
###begin article-title 70
Regulation of leukotrienes in the management of asthma: biology and clinical therapy
###end article-title 70
###begin article-title 71
Cysteinyl leukotriene receptors
###end article-title 71
###begin article-title 72
###xml 24 29 <span type="species:ncbi:9606">human</span>
Characterization of the human cysteinyl leukotriene 2 receptor
###end article-title 72
###begin article-title 73
Prostanoid and leukotriene receptors: a progress report from the IUPHAR working parties on classification and nomenclature
###end article-title 73
###begin article-title 74
###xml 43 48 <span type="species:ncbi:9606">human</span>
A second cysteinyl leukotriene receptor in human lung
###end article-title 74
###begin article-title 75
Cysteinyl-leukotriene receptors in pulmonary vessels
###end article-title 75
###begin article-title 76
###xml 49 54 <span type="species:ncbi:9606">human</span>
Levels of cysteinyl leukotriene receptor mRNA in human peripheral leucocytes: significantly higher expression of cysteinyl leukotriene receptor 2 mRNA in eosinophils
###end article-title 76
###begin article-title 77
###xml 74 79 <span type="species:ncbi:9606">human</span>
Expression of the type 2 receptor for cysteinyl leukotrienes (CysLT2R) by human mast cells: Functional distinction from CysLT1R
###end article-title 77
###begin article-title 78
Concordant modulation of cysteinyl leukotriene receptor expression by IL-4 and IFN-gamma on peripheral immune cells
###end article-title 78
###begin article-title 79
Leukotriene pathway genetics and pharmacogenetics in allergy
###end article-title 79
###begin article-title 80
A genome-wide search for quantitative trait loci underlying asthma
###end article-title 80
###begin article-title 81
Linkage and association of atopic asthma to markers on chromosome 13 in the Japanese population
###end article-title 81
###begin article-title 82
Association analysis of cysteinyl-leukotriene receptor 2 (CYSLTR2) polymorphisms with aspirin intolerance in asthmatics
###end article-title 82
###begin article-title 83
The cysteinyl leukotriene receptors
###end article-title 83
###begin article-title 84
International Union of Pharmacology XXXVII. Nomenclature for leukotriene and lipoxin receptors
###end article-title 84
###begin article-title 85
###xml 164 168 <span type="species:ncbi:10090">mice</span>
Targeted gene disruption reveals the role of the cysteinyl leukotriene 2 receptor in increased vascular permeability and in bleomycin-induced pulmonary fibrosis in mice
###end article-title 85
###begin article-title 86
Expression of the cysteinyl leukotriene receptors cysLT(1) and cysLT(2) in aspirin-sensitive and aspirin-tolerant chronic rhinosinusitis
###end article-title 86
###begin article-title 87
Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells
###end article-title 87

